Skip to main content

Новости и события

eSRS symposium

Register for the eSRS Satellite Symposium : From new tracers developments to routine clinical applications on Synthera® + platform

PET modality is one of the most rapidly growing area of medical imaging thanks to the availability of innumerous clinical centers with their own cyclotrons. To be able to cover the growing clinical demands, radiopharmacies are developing new tracers while keeping up their routine production in a (c)GMP environment.  In this symposium, Dr. Ida Nymann Petersen, PhD. and Dr. Vasko Kramer, PhD.will share their experience in the development of new tracers on the Synthera® Platform.  When?  May 20th 4-5pm CET (Central European Time)   REGISTER What will you learn ?   Synthesis of [18F]mFBG and [18F]FE-PE2I on Synthera®+ platform By Dr. Ida Nymann Petersen, PhD., Radiochemist at Rigshospitalet in Copenhagen, Denmark.   In this talk, the fully automated labelling of [18F]mFBG and [18F]FE-PE2I on the Synthera®+ and Synthera®+ HPLC platform will be presented. [18F]FE-PE2I was synthesized in 32 % RCY, 98 % RCP in 40 min. [18F]mFBG is currently under optimization.    Development of new tracers: from neurology to oncology applications. By Dr. Vasko Kramer, PhD., Head of Research & Development at Positron Pharma in Santiago, Chile.  He will present some of their results for the production and development of new, innovative PET imaging agents for neurological ([18F]F-PR04.MZ, [18F]F-Florbetaben, [18F]F-PI-2620), oncological ([18F]FAPi-74, [18F]F-AlF-NOTA-Octreotide), and research applications (7-[18F]F-Fluoro-tryptophan, 18F-Tetrazines) using a compact, cassette-based synthesis platform.     You can join this symposium even if you don’t attend eSRS meeting.
Читать далее
SBRT and PSMA

Watch the webinar: The Role of Specific PET PSMA imaging and SBRT in the Management of Prostate Cancer

Thank you  Dr. Jeremie Calais, Dr. Stefan Korber and Dr. Kai Schubert for your instructive presentations!  Did you miss the webinar? Watch the recording In addition to all questions answered at the end of this webinar, here are a few remaining ones, which the speakers kindly answered: Do you think that PET imaging in treatment position needs to be done systematically (in order to decrease irradiation dose exposure) ? Dr Calais: No. This is not like head and Neck or lung. Rectal and bladder filling are too complex to really have exact repositioning from PSMA PET to treatment table. Dr Schubert: Treatment position is not absolutely necessary, of course favorable. Different positions between treatment planning CT and ‘diagnostic’ imaging can be taken care of by deformable image registration, but there are limitations and additional QA would be necessary.   Is there any comparison between PSMA-Targeted therapy and SBRT?  Dr Calais :  No (not yet). Trials of PSMA MRT for oligometastatic disease are underway. My personal opinion is that it may not be the best application as a single agent therapy because the local control is inferior than with SBRT. However it can treat the microscopic and small lesions, so maybe the combination of both is probably a good approach.   When should we re-image after PSMA guided MDT? after changes in PSA? Dr Calais : At least 4 months after the end of SBRT ( for the local control).Otherwise if suspicion of new lesions based on PSA rise after NADIR or other imaging suspicion or clinical symptom. Dr Korber: I think, checking the PSA is adequate. Sure, if the PSA is rising again, new imaging (e.g. another PSMA-PET/CT) should be evaluated.
Читать далее
Yves

IBA is launching a new cyclotron for its 35th anniversary

This year, IBA celebrates its 35th anniversary. 35 years of an incredible journey that began in the 1980s and that would change the lives of thousands of cancer patients. And mine too, of course! Because believe me, if the engineer I was at the time had been able to see all that has been achieved to date, he would never have believed it! And by the way, in terms of groundbreaking technology, there is a lot more to come soon! But that’s another story… For now, let’s go back to this journey and how it all started when I designed the first IBA Cyclotron : the Cyclone. My objective was to increase cyclotrons energetic efficiency by a factor 15: three times less electrical consumption for five times more beam power. Something nobody believed would be possible at the time! But the first prototype was a great success which led to the birth of Ion Beam Applications: IBA, allowing us to make the diagnosis of cancer and other critical diseases accessible for many patients around the world through PET and SPECT imaging. While also pioneering the advancement of protontherapy with 100.000 patients treated worldwide to this day. You could say that saving people’s life is my life’s work. Something we’re particularly proud of here at IBA ! Yet, we are not surgeons. Nor doctors. But we are here for the patients. They do not see us, but we do. Since more than 35 years. But the birthdays that really matter are those of people who were saved by IBA’s technology. Birthdays they can continue to celebrate. Because we know that every year that is taken away from the disease counts for three. So, long life to all cancer patients and long life to IBA! But our innovation story doesn’t stop here. We are beaming proud to announce the arrival of a new cyclone, fresh from our Beam Factory! The culmination of 35 years of experience and groundbreaking research. Get ready to be amazed… Yves Jongen, IBA Founder
Читать далее

О нас

Опираясь на 35-летний опыт, IBA RadioPharma Solutions помогает центрам ядерной медицины проектировать, строить и эксплуатировать отделения ПЭТ для производства радиофармпрепаратов, используемых для диагностики и лечения рака и других критических заболеваний.

IBA будут работать с вами и поддерживать в течение всего процесса — на первой встрече, при проектировании, монтаже и введении в эксплуатацию. Более того, эксперты IBA будут сопровождать вас на протяжении всего срока службы радиофармацевтического оборудования: проводить обучение, выполнять необходимые обновления и техническое обслуживание, чтобы обеспечить успех вашего проекта в соответствии с принципами устойчивого развития.

Читать далее
Who we are

Основные факты

до <strong>30 </strong>Ки

За один производственный цикл.

Для производства ФДГ.

до <strong>3</strong>

Модулей синтеза в одной горячей камере.

Мультипроизводство нескольких РФП

<strong>500</strong> +

модулей радиохимического синтеза Synthera® установлены в разных странах мира.

<strong>300</strong> +

циклотронов эксплуатируются и обслуживаются на 5 континентах.